S&P Global set a €25.00 ($29.07) price target on Rhoen Klinikum AG (ETR:RHK) in a research note published on Friday morning. The brokerage currently has a sell rating on the stock.

RHK has been the subject of a number of other reports. Warburg Research set a €26.00 ($30.23) target price on Rhoen Klinikum AG and gave the company a neutral rating in a research note on Thursday, August 3rd. Independent Research GmbH set a €28.00 ($32.56) target price on Rhoen Klinikum AG and gave the company a neutral rating in a research note on Monday, August 14th. Commerzbank Ag set a €25.00 ($29.07) target price on Rhoen Klinikum AG and gave the company a neutral rating in a research note on Monday, September 18th. DZ Bank AG restated a sell rating on shares of Rhoen Klinikum AG in a research note on Tuesday, August 29th. Finally, Berenberg Bank set a €26.50 ($30.81) target price on Rhoen Klinikum AG and gave the company a neutral rating in a research note on Monday, August 7th. Four research analysts have rated the stock with a sell rating and six have issued a hold rating to the stock. The stock has a consensus rating of Hold and an average price target of €24.49 ($28.48).

Shares of Rhoen Klinikum AG (ETR RHK) traded down €0.05 ($0.06) during trading hours on Friday, hitting €30.28 ($35.21). The stock had a trading volume of 50,307 shares, compared to its average volume of 71,176. Rhoen Klinikum AG has a 52 week low of €22.66 ($26.35) and a 52 week high of €30.65 ($35.64).

COPYRIGHT VIOLATION WARNING: “Rhoen Klinikum AG (RHK) Given a €25.00 Price Target at S&P Global” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.watchlistnews.com/rhoen-klinikum-ag-rhk-given-a-25-00-price-target-at-sp-global/1696399.html.

Rhoen Klinikum AG Company Profile

RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services in the areas of cardiological and coronary diseases, neurological disorders, oncology, lung diseases, and orthopedic and accident surgeries; rehabilitation services; and thoracic, pulmonary and vascular diseases, tumors, heart conditions, and nervous and skeletal system diseases.

Analyst Recommendations for Rhoen Klinikum AG (ETR:RHK)

Receive News & Ratings for Rhoen Klinikum AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhoen Klinikum AG and related companies with Analyst Ratings Network's FREE daily email newsletter.